Management of Elevated Liver Enzymes

Pattern Recognition and Initial Assessment

The American Association for the Study of Liver Diseases recommends that an ALT:AST ratio >1 is typical of non-alcoholic liver diseases, whereas alcoholic liver disease typically shows an AST:ALT ratio >1 1
The elevation is considered mild to moderate if ALT is less than 3 times the upper limit of normal (ULN), assuming a ULN of approximately 40-50 U/L 2, 3

The European Association for the Study of the Liver recommends a complete viral hepatitis screen (Hepatitis A, B, C, E) as part of the initial diagnostic workup 4, 5
The American Gastroenterological Association suggests assessing alcohol use using validated tools (e.g., AUDIT-C, AUDIT) 1, 6
Metabolic risk factor assessment (BMI, diabetes, dyslipidemia, hypertension) for non-alcoholic fatty liver disease (NAFLD) is recommended by the American Association for the Study of Liver Diseases 4, 5
Medication review for potential drug-induced liver injury is recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 7, 3

The American College of Gastroenterology recommends no immediate drug discontinuation or intervention at mild to moderate levels of liver enzyme elevation unless symptoms of liver dysfunction are present 2, 7
Repeat liver enzymes in 2-5 days to establish a trend (increasing, stable, or decreasing) is suggested by the European Association for the Study of the Liver 2, 3
If alcohol-related, the American Association for the Study of Liver Diseases recommends alcohol cessation and consideration of referral to alcohol services if the AUDIT score is >19 1, 6
If NAFLD-related, lifestyle modifications (weight loss, exercise) and fibrosis risk assessment using FIB-4 or NAFLD Fibrosis Score are recommended by the American Association for the Study of Liver Diseases 4, 5, 6
If medication-related, consideration of modification or discontinuation of suspected hepatotoxic medications and monitoring of liver enzymes after medication changes is recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 7, 3

The American College of Gastroenterology recommends referral to a specialist if ALT continues to rise or remains elevated >2× ULN after 3 months despite addressing modifiable factors 4, 5
Referral is also recommended if there is evidence of synthetic dysfunction (elevated INR, low albumin) or clinical signs of chronic liver disease or cirrhosis 2, 4, 5
Imaging suggesting advanced fibrosis, cirrhosis, or focal lesions is also a referral criterion, as recommended by the European Association for the Study of the Liver 4, 6

Laboratory tests should include serum creatinine, complete blood count, and additional liver function tests (bilirubin, albumin, INR) 8
For patients on medications requiring monitoring: check liver enzymes approximately every 3-4 months for stable doses with no history of abnormal results 8
For patients on NSAIDs with elevated enzymes, periodic measurements of liver enzymes approximately twice yearly for chronic daily use and once yearly for routine use 8
For patients on TNFα inhibitors, measure liver enzymes approximately every 3-6 months 8